{
    "Patient Information": {
        "Patient ID": "1636",
        "Patient Name": "Jessica Moore",
        "Date of Birth": "1941-07-06",
        "Age": 83,
        "Gender": "Male",
        "Contact Information": "N/A",
        "Address": "N/A"
    },
    "Diagnosis Information": {
        "Diagnosis Center": "N/A",
        "Doctor Name": "Dr. Philip Thompson",
        "Accession Number": "N/A",
        "Date of Diagnosis": "N/A",
        "Date of Report Issuance": "N/A",
        "CLIA Number": "N/A",
        "Laboratory Medical Director ": "N/A",
        "Method of Analysis": [
            "Seq",
            "IHC",
            "NGS"
        ],
        "Pipeline Version (Report Version)": "N/A"
    },
    "Cancer Information": {
        "Cancer Type": "Follicular lymphoma",
        "Cancer Stage": "Not explicitly stated",
        "Cancer Grade": "Not explicitly stated",
        "Cancer Location in the Body": "Lymphoma",
        "Tumor Specimen Source": "Spleen",
        "Tumor Percentage in Sample": "N/A",
        "Normal Specimen Source": "N/A",
        "Date of Tumor Sample Collection": "2023-07-01",
        "Date Tumor Sample Received": "2023-07-04",
        "Date of Normal Sample Collection": "N/A",
        "Date Normal Sample Received": "N/A"
    },
    "Biomarkers": {
        "General Biomarkers": {
            "Microsatellite Instability (MSI)": "Equivocal",
            "Tumor Mutational Burden (TMB)": "6 mutations/Mb Low",
            "Tumor Mutational Burden Percentile": "N/A",
            "Loss of Heterozygosity (LOH)": "Low - 8% of tested genomic segments exhibit LOH",
            "Mismatch Repair (MMR) Status": [
                "Positive| 3+, 76%"
            ],
            "PDL1 Expression": [
                "Positive| 1+, 25%"
            ],
            "EBV (Epstein-Barr Virus) Status": "N/A",
            "Other Immunotherapy Markers": "N/A",
            "Low-Coverage Regions (Indeterminate Genes)": [
                "HDAC1",
                "KIT",
                "MYOD1"
            ]
        },
        "Gene Mutations": [
            {
                "Gene Name": "EGFR",
                "DNA Mutation Description": "c.3113A>G",
                "Protein Variant": "p.H1038R",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 6,
                "Variant Allele Fraction": "20.25",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Likely Pathogenic",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "NT5C2",
                "DNA Mutation Description": "c.1508G>C",
                "Protein Variant": "p.G503A",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 8,
                "Variant Allele Fraction": "11.15",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Likely Benign",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "APC",
                "DNA Mutation Description": "c.1162G>A",
                "Protein Variant": "p.G388R",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 7,
                "Variant Allele Fraction": "21.7",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Benign",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "PKLR",
                "DNA Mutation Description": "c.1100G>A",
                "Protein Variant": "p.R367Q",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 6,
                "Variant Allele Fraction": "16.25",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Likely Benign",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "HBA2",
                "DNA Mutation Description": "N/A",
                "Protein Variant": "N/A",
                "Mutation Effect": "Fusion not detected",
                "Functional Impact": "N/A",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "N/A",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "RNA-Tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "CSF1R",
                "DNA Mutation Description": "N/A",
                "Protein Variant": "N/A",
                "Mutation Effect": "Mutation not detected",
                "Functional Impact": "N/A",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "N/A",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA-Tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "JAK3",
                "DNA Mutation Description": "N/A",
                "Protein Variant": "N/A",
                "Mutation Effect": "Stable",
                "Functional Impact": "N/A",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "N/A",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA-Tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            }
        ],
        "Immunochemistry Biomarkers": [
            {
                "Biomarker Name": "PR",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "2+, 3%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "AR",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "1+, 7%",
                "Interpretation": "Negative"
            },
            {
                "Biomarker Name": "PD-L1(SP142)",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "1+, 25%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "PTEN",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "3+, 72%",
                "Interpretation": "Negative"
            },
            {
                "Biomarker Name": "ER",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "2+, 21%",
                "Interpretation": "Negative"
            }
        ]
    },
    "Therapeutic Information": {
        "FDA-Approved Therapies for Current Diagnosis": [
            {
                "Therapy Name": "abemaciclib, palbociclib, ribociclib, endocrine, therapy, everolimus",
                "Therapy Type": "targeted therapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "ER",
                    "Biomarker level": "level 2",
                    "Positively/Negatively Associated": "BENEFIT"
                }
            },
            {
                "Therapy Name": "abemaciclib, palbociclib, ribociclib, endocrine therapy",
                "Therapy Type": "targeted therapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "PR",
                    "Biomarker level": "level 2",
                    "Positively/Negatively Associated": "BENEFIT"
                }
            },
            {
                "Therapy Name": "pembrolizumab",
                "Therapy Type": "immunotherapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "TMB",
                    "Biomarker level": "level 2",
                    "Positively/Negatively Associated": "BENEFIT"
                }
            },
            {
                "Therapy Name": "trastuzumab, ado-trastuzumab emtansine, pertuzumab, fam-trastuzumab deruxtecan-nxki, lapatinib, neratinib, tucatinib",
                "Therapy Type": "targeted therapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "ERBB2",
                    "Biomarker level": "level 1",
                    "Positively/Negatively Associated": "LACK OF BENEFT"
                }
            }
        ],
        "FDA-Approved Therapies for Other Indications": []
    },
    "Clinical Trials": [
        {
            "Trial Title": "Anti hormonal therapy",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Chemotherapy",
            "Medication": "anastrazole, letrozole, exemestane, fulvestrant, tamoxifen, goserelin, leuprolide",
            "Associated Mutations": [
                "ER"
            ]
        },
        {
            "Trial Title": "Anti hormonal therapy",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Chemotherapy",
            "Medication": "anastrazole, letrozole, exemestane, fulvestrant, tamoxifen, goserelin, leuprolide",
            "Associated Mutations": [
                "PR"
            ]
        },
        {
            "Trial Title": "Anti inflammatory agents",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Chemotherapy",
            "Medication": "aspirin",
            "Associated Mutations": [
                "PIK3CA"
            ]
        },
        {
            "Trial Title": "Akt inhibitors",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "AZD5363, MK-2206, ipataserib",
            "Associated Mutations": [
                "ARID1A"
            ]
        },
        {
            "Trial Title": "immunomodulatory agents",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "avelumab, atezolizumab, durvalumab, ipilimumab, nivolumab, pembrolizumab",
            "Associated Mutations": [
                "TMB"
            ]
        },
        {
            "Trial Title": "PARP inhibitors",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "BGB-290, BMN-673, olaparib, rucaparib, talazoparib",
            "Associated Mutations": [
                "NBN"
            ]
        },
        {
            "Trial Title": "Akt/mTor inhibitors",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "AZD5363, BYL719, MK-2206, ipataserib, everolimus, temsirolimus",
            "Associated Mutations": [
                "PIK3CA"
            ]
        }
    ],
    "Variants of Unknown Significance (VUS)": [
        {
            "Gene Name": "PTEN",
            "DNA Alteration": "c.1A>G",
            "Protein Variant": "p.M1V",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "21.64",
            "Exon Number": 7,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        },
        {
            "Gene Name": "KRAS",
            "DNA Alteration": "c.2207_2212delinsTAGATTC",
            "Protein Variant": "p.Y736fs*4",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "13.75",
            "Exon Number": 8,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        },
        {
            "Gene Name": "RNF43",
            "DNA Alteration": "c.3583A>T",
            "Protein Variant": "p.T1195S",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "3.9",
            "Exon Number": 15,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        }
    ],
    "Additional Indicators": []
}